歐洲慢性靜脈疾病診療指南 | ESVS前言篇三

☆ 1.指南編寫委員會 ☆

    指南編寫委員會（Guideline Writing Committee，GWC）的成員由ESVS選出，包括血管外科醫生、血管內科醫生、介入放射科醫生和婦產科醫生等代表參與CVD治療的臨床醫生。正如介紹性會議所商定，所有委員會成員都參與了各自負責章節和段落的證據選擇和評級工作（參見附錄主題、檢索詞和責任作者的補充表）。GWC的所有成員都參與了最后推薦意見的制定。

    委員會成員提供了所有可能被視為確實的或潛在利益沖突來源關系的披露聲明。這些文件已歸檔，可在ESVS總部獲得。成員在制定指南過程中，沒有得到任何制藥、器械或外科行業的資金支持。

☆2.指南制定工作流程☆

         GWC于2019年11月在荷蘭阿姆斯特丹舉行了一次介紹性會議，會上確定了主題和作者任務清單。委員會成員的意見由主席和聯合主席匯編成指南草案。在完成初稿并經過內部審查后，委員會于2020年9月在德國法蘭克福再次召開會議審查并核準了每項建議的措辭。指南隨后經歷了三輪外部審查，并進行了適當的修訂。

☆ 1. Guideline Writing Committee. ☆ 

       Members of the Guideline Writing Committee (GWC) were selected by the ESVS to represent clinicians involved in the treatment of CVD and included vascular surgeons, vascular physicians, an interven tional radiologist, and a gynaecologist-obstetrician. All members of the GWC were involved in selecting and rating the evidence for each of the different chapters and subsections under their responsibility (see Appendix with Supplementary Table of topics, search terms, and responsible authors), as agreed in the introductory meeting. All GWC members were involved in formulating the final recommendations.

       GWC members have provided disclosure statements regarding all relationships that might be perceived as real or potential sources of conflicts of interest. These are filed and available at the ESVS headquarters. GWC members received no financial support from any pharmaceutical, device, or surgical industry to develop these guidelines.

☆2. Workflow for producing the guidelines.☆

       The GWC held an introductory meeting in November 2019 in Amsterdam, Netherlands, at which the list of topics and author tasks were determined. Contributions from GWC members were compiled into a draft of the guidelines by the chair and co-chair. After the first draft was completed and internally reviewed, the GWC met again in September 2020 in Frankfurt, Germany, to review and approve the wording of each recommendation. The guidelines then underwent three rounds of external reviews, and appropriate revisions were implemented.

☆ 3. Literature search. ☆

       GWC members agreed on a common sys tematic literature search strategy for each of the chapters. A comprehensive literature search of articles published was performed using MEDLINE (through PubMed), Embase, Car diosource Clinical Trials Database, and the Cochrane Library databases between 1 January 2013 and 30 June 2020, for relevant papers published in English.The search terms used for the different chapters and subsections are mentioned in the Appendix (Supplementary Table). Reference checking and manual search by the GWC members added other relevant literature. Only peer reviewed, published literature and studies presenting pre-defined outcomes were considered. The selection process followed the “pyramid of evidence”, with aggregated evidence at the top of the pyramid (meta analyses of several randomised controlled trials [RCTs], other meta-analyses, and systematic reviews), followed by RCTs and finally observational studies. Single case reports, abstracts, and in vitro studies were excluded, leaving expert opinion at the bottom of the pyramid. Articles published after the search date or in another language were included only if they were of paramount importance to this guideline. After the first and second external review, the members of the GWC performed a second and third literature search within their area of responsibility to determine if any important publications had been published between July 2020 and February 2021, and further until the end of June 2021, respectively.